# NCT03194542 (NCT03194542)

> A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03194542
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Primary Myelofibrosis; Anemia
- Interventions: Luspatercept
- Enrollment: 95
- Primary outcome: The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period

## Commentary we found

- X threads: 4
- YouTube: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03194542